BioCentury
ARTICLE | Clinical News

EpiCept NP-1: Additional Phase IIb data

February 14, 2011 8:00 AM UTC

A double-blind, U.S. Phase IIb trial in >460 patients with painful CPN for at least 28 days following chemotherapy showed that twice-daily 4 mL topical EpiCept NP-1 for 6 weeks met the primary endpoin...